ABSTRACT: Objectives: This study was conducted to assess pregnancy outcomes in women with systemic lupus erythematosus (SLE) in Oman. Methods: A retrospective cohort study of 149 pregnancies in 98 women with SLE was conducted over 10 years to evaluate the impact of clinical and laboratory parameters in predicting adverse pregnancy outcomes. Results: Mean maternal age was 30.6 ± 5 years ranging from 20–44 years, and the mean disease duration was 10 ± 5 years, ranging from 2–27 years. The most common maternal manifestations were joint pain in 36 (24.2%), lupus nephritis (LN) in 18 (12.08%), preeclampsia in 11 (7.4%), eclampsia in three (2%) and lupus flare in one pregnancy. The live birth rate was 139 (93.3%) with a mean gestational age of 36 ± 2 weeks ranging from 26–40 weeks. In total, 55 (39.6%) were preterm deliveries, six (4%) pregnancies ended in miscarriage, and four (2.7%) resulted in intrauterine fetal death. Intrauterine growth restriction was observed in 49 babies (35%). A significant association was found between hypertension (HTN) and miscarriage \( (P = 0.024) \) and preterm birth \( (P = 0.019) \). In addition, HTN was positively associated with preeclampsia \( (P = 0.004) \) and LN \( (P = 0.048) \). Antiphospholipid syndrome impacted preterm birth \( (P = 0.013) \) and postpartum haemorrhage (PPH) \( (P = 0.027) \) and was found to be a significant predictor for women developing deep vein thrombosis and pulmonary embolism \( (P < 0.001) \) for both. Conclusion: Despite potential complications, most pregnancies complicated by SLE in Oman result in good outcomes. Adverse pregnancy outcomes, however, may still occur in women with SLE. In women with SLE, pregnancy planning, careful antenatal monitoring and efficient SLE treatment need to be undertaken for successful pregnancy outcomes.

Keywords: Systemic Lupus Erythematosus; Pregnancy Outcomes; Lupus Nephritis; Antiphospholipid Antibodies; Neonatal Lupus.
complications in pregnant women with SLE were lupus flare (26%), HTN (16%), nephritis (16%), preeclampsia (8%) and eclampsia (1%). Fetal outcomes reported by the same study were spontaneous abortion (16%), neonatal death (3%), stillbirth (4%), intrauterine growth restriction (IUGR; 13%) and premature birth (39%). Finally, prematurity birth rate, active nephritis and increased HTN rates in patients with active nephritis or a history of nephritis were found to increase the risk of adverse fetal and maternal outcomes. A positive and significant correlation was found between nephritis history and preeclampsia as well as aPL antibodies and premature birth, and HTN and an increased rate of induced abortions. Both LN and anti-aPL antibodies exacerbated both maternal HTN and premature birth.  

Understanding the association between SLE and pregnancy is critical for healthcare providers in order to improve women's care and pregnancy outcomes. The recommendations, therefore, are that pregnancies should be planned, SLE should be in remission for a minimum of six months and medications should be adjusted prior to pregnancy.  

Sultan Qaboos University Hospital (SQUH) is a tertiary hospital in Oman with multiple specialties, including a rheumatology unit and an obstetrics and gynaecology department with a maternal medicine team. The hospital receives patients from all over Oman, including far reaching areas, through the Emergency Department. Since pregnant women with SLE are mainly managed at two tertiary centres in Oman, the aim of this study was to share experiences and lessons learned from managing those patients at SQUH. This study was conducted by evaluating maternal and fetal outcomes and complications in pregnant women with SLE who were followed up and delivered at SQUH. This study aimed to determine risk factors that predict adverse outcomes for women with SLE and their babies.  

Methods  

A retrospective cohort study was conducted at SQUH from August 2006 to January 2016 and included 149 pregnancies in 98 women with SLE which met the American College of Rheumatology (ACR) 1997 classification criteria. Delivery and neonatal ward registries were reviewed after obtaining ethical approval from the Ethics Committee of the College of Medicine and Health Sciences at Sultan Qaboos University (SQU). Pregnant women diagnosed with SLE who were in remission were included in the study. All patients were on prednisolone, hydroxychloroquine and aspirin as a standard of care. They were closely monitored during pregnancy with close follow-ups by maternal medicine specialists and rheumatologists who looked for symptoms and signs of lupus flare and adverse pregnancy outcomes. Patients with missing data, who delivered elsewhere, with disease activity just prior to pregnancy or who had been diagnosed with SLE during pregnancy were excluded from the study.  

Collected maternal demographics included age, gravidity, parity, duration of disease, history of deep vein thrombosis (DVT), pulmonary embolism (PE), diabetes mellitus (DM), HTN, previous miscarriages, Caesarean section (CS) and intrauterine fetal death (IUFD).  

Laboratory characteristics collected included anti-Sjögren syndrome-A (SSA)/anti-Ro, anti-Sjögren syndrome-B (SSB)/anti-La, lupus anticoagulant (LAC), anti-cardiolipin antibody (aCL), anti-beta-2 glycoprotein 1 antibodies (anti-B2GPI), anti-double stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA), C-reactive protein (CRP), complement 3 (C3), complement 4 (C4) and vitamin D3 levels.  

Maternal outcomes reviewed included mode of delivery, gestational age at delivery and obstetrical complications. Complications included preeclampsia (i.e. gestational HTN with proteinuria), eclampsia (i.e. gestational HTN followed by one or more convulsions or coma as a consequence of convulsion), antepartum haemorrhage (APH) (i.e. prepartum bleeding starting from 22 gestational weeks) and postpartum haemorrhage (PPH) (i.e. 500–1000 mL or more of blood lost within 24 hours following delivery). Disease manifestations reviewed included SLE flare, LN, the presence of antiphospholipid syndrome (APS), joint pain and involvement of other organs such as the heart. Fetal outcomes included miscarriage before 20 gestational weeks, IUFD or IUGR with an estimated fetal weight less than the tenth centile, birth weight, Apgar scores, admission to the neonatal intensive care unit (NICU), congenital heart block, prematurity and neonatal lupus.  

Descriptive statistics were used to summarise data. Mean and standard deviation (SD) were used for continuous variables. For categorical variables, frequencies and percentages were reported. Continuous variables were analysed using Student’s t-test where the distribution was normal. A Chi-squared test was used to evaluate the impact of clinical and laboratory characteristics on maternal and fetal outcomes. For cell frequencies ≤5, Fisher’s exact test was used. Significant predictors of adverse pregnancy outcomes (i.e. miscarriage, CS, prematurity, IUFD, SLE flare, LN, joint pain, DVT, PE, preeclampsia, eclampsia, APH and PPH) were further analysed using multivariable logistic
regression and odds ratios (OR) with 95% confidence intervals (CI). Each pregnancy was considered a separate observation. In all cases, a P-value of <0.05 was considered statistically significant. All statistical analyses were performed using STATA, Version 13 (StataCorp, College Station, Texas, USA).

Results
In total, 149 pregnancies in 98 women with SLE were studied. Mean maternal age was 30.6 ± 5 years (range: 20–44), and the mean disease duration was 10 ± 5 years (range: 2–27). According to the SLEDAI index, all patients were in clinical remission. Previous pregnancy complications included miscarriages (n = 50; 33.56%), IUFD (n = 24; 16.22%), CS (n = 38; 25.50%), DVT (n = 19; 12.75%), PE (n = 9; 6.04%), preeclampsia (n = 8; 5.41%) and eclampsia (n = 2; 1.35%) [Table 1].

Clinical manifestations of SLE across the current pregnancies included arthritic joint pain (n = 36; 24.2%), LN (n = 18; 8%), preeclampsia (n = 11; 7.4%) and eclampsia (n = 3; 2%). APH and PPH were seen in two (1.3%) and eight (5.4%) pregnancies, respectively. Only one patient had lupus flare. This patient presented with joint pain at 23 gestational weeks and was managed with high-dose prednisolone. The patient was a 21-year-old primigravida with known SLE for two years. Her disease was in remission. Unfortunately, she experienced IUFD at 26 gestational weeks [Table 2].

Laboratory investigations were also considered. Positive ANA was found in 83 (56%) and positive anti-dsDNA antibodies in 80 (54%) pregnancies. CRP was elevated in 53 (36%) pregnancies. Anti-SSA and anti-SSB were positive in 68 (48.57%) and 15 (10.87%) pregnancies, respectively. In total, 25 patients (16.78%) had documented secondary APS prior to the current pregnancy. Positive anti-beta-2 glycoprotein1 antibodies were seen in 17 (11%) pregnancies as IgM antibodies while IgG was found in two (1.3%) pregnancies. aCL IgG positive while nine (6.04%) pregnancies were aCL IgM positive. In addition, seven (4.70%) pregnancies had positive LAC. Furthermore, C3 and C4 were below the normal level in about 21 (14.09%) and seven (5%) pregnancies, respectively, but these patients were asymptomatic for lupus flare. Regarding

![Table 1: Maternal demographics of patients diagnosed with systemic lupus erythematosus who presented at Sultan Qaboos University Hospital from August 2006 to January 2016 (N = 149)](image)

| Variable          | Number of pregnancies | Percentage | Range (Mean; SD) |
|-------------------|-----------------------|------------|------------------|
| Age               | -                     | -          | 20–44 (30.6; 5)  |
| Gravidity         | -                     | -          | 1–12 (3.8; 2.4)  |
| Parity            | -                     | -          | 0–8 (2; 1.7)     |
| History of miscarriages | 50            | 33.56     | -                |
| History of DVT    | 19                    | 12.75      | -                |
| History of PE     | 9                     | 6.04       | -                |
| History of DM     | 51                    | 34.46      | -                |
| History of HTN    | 18                    | 12.16      | -                |
| History of CS     | 38                    | 25.50      | -                |
| History of preeclampsia | 8              | 5.41       | -                |
| History of eclampsia | 2               | 1.35       | -                |
| History of IUFD   | 24                    | 16.22      | -                |
| LN                | 18                    | 12.08      | -                |

SD = standard deviation; DVT = deep vein thrombosis; PE = pulmonary embolism; DM = diabetes mellitus; HTN = hypertension; CS = Caesarean section; IUFD = intrauterine fetal death; LN = lupus nephritis.

![Table 2: Current pregnancy outcomes of patients diagnosed with systemic lupus erythematosus who presented at Sultan Qaboos University Hospital from August 2006 to January 2016 (N = 149)](image)

| Variable          | Number of pregnancies | Percentage |
|-------------------|-----------------------|------------|
| Neatnental outcomes | -                     | -          |
| Live delivery     | 139                   | 93.3       |
| Miscarriage       | 6                     | 4.0        |
| IUFD              | 4                     | 2.7        |
| Mode of delivery  | -                     | -          |
| CS                | 47                    | 33.8       |
| SVD               | 89                    | 64         |
| Assisted          | 3                     | 2.2        |
| Preterm delivery (<37 weeks) | 55         | 39.6       |
| Eclampsia         | 3                     | 2.0        |
| Preeclampsia      | 11                    | 7.4        |
| APH               | 2                     | 1.3        |
| PPH               | 8                     | 5.4        |
| Joint pain        | 36                    | 24.2       |
| DVT               | 26                    | 17.0       |
| PE                | 11                    | 7.4        |
| Worsening LN      | 18                    | 8.0        |

IUFD = intrauterine fetal death; CS = Caesarean section; SVD = spontaneous vaginal delivery; APH = antepartum haemorrhage; PPH = post-partum haemorrhage; DVT = deep vein thrombosis; PE = pulmonary embolism; LN = lupus nephritis.
Table 3: Association of laboratory parameters and maternal lupus disease activity with adverse pregnancy outcomes (N = 149)

| Clinical and Lab findings | MC Fetal Loss | IUFD | PTB | CS | LN | Joint pain | APH | PPH | E | Pre-E | DVT | PE |
|---------------------------|--------------|------|-----|----|----|------------|-----|-----|---|-------|-----|----|
| HTN Yes (n = 18)          | 3            | 3    | 0   | 12 | 9  | 5          | 1   | 0   | 3 | 0     | 5   | 4  |
| No (n = 130)              | 3            | 7    | 4   | 47 | 42 | 13         | 35  | 18  | 5 | 3     | 6   | 21 |
| P value                   |              | 0.024| 0.105| 1.0 | 0.019| 0.139      | 0.048| 0.074| 1.0| 0.058| 1.0 | 0.004|
| DM                        |              |      |     |    |    |            |     |     |   |       |     |    |
| Yes (n = 51)              | 4            | 5    | 1   | 16 | 18 | 9          | 9   | 1   | 3 | 0     | 2   | 14 |
| No (n = 97)               | 2            | 5    | 3   | 43 | 33 | 9          | 27  | 1   | 5 | 3     | 9   | 11 |
| P value                   |              | 0.182| 0.314| 1.0 | 0.074| 0.185      | 0.227| 1.0  | 1.0| 0.551| 0.331| 0.013|
| APS                       |              |      |     |    |    |            |     |     |   |       |     |    |
| Yes (n = 25)              | 3            | 4    | 1   | 16 | 10 | 2          | 6   | 0   | 4 | 0     | 1   | 8  |
| No (n = 124)              | 3            | 6    | 3   | 44 | 41 | 16         | 30  | 2   | 4 | 3     | 10  | 19 |
| P value                   |              | 0.059| 0.064| 0.524| 0.013| 0.505      | 0.739| 0.984| 1.0| 0.027| 1.0 | 0.691|
| SSA/ Anti-Ro Positive     |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 68)                  | 1            | 2    | 1   | 33 | 18 | 7          | 18  | 0   | 4 | 3     | 7   | 9  |
| Negative                  |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 72)                  | 5            | 7    | 2   | 25 | 32 | 10         | 18  | 2   | 4 | 0     | 2   | 15 |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 9)                   |              | 0.108| 0.09 | 1.0 | 0.106| 0.027      | 0.609| 0.842| 0.497| 1.0 | 0.112| 0.09 |
| SSB/ Anti-La Positive     |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 15)                  | 0            | 0    | 0   | 7  | 2   | 1          | 6   | 0   | 1 | 0     | 0   | 1  |
| Negative                  |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 123)                 | 6            | 9    | 3   | 49 | 46 | 16         | 30  | 2   | 7 | 3     | 9   | 23 |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 11)                  |              | 1.0  | 0.597| 0.612| 0.704| 0.085      | 0.694| 0.194| 1.0| 1.0   | 1.0 | 0.597|
| Low C3                    |              |      |     |    |    |            |     |     |   |       |     |    |
| Yes (n = 21)              | 0            | 0    | 0   | 11 | 13 | 3          | 9   | 0   | 1 | 2     | 5   | 2  |
| No (n = 122)              | 6            | 9    | 3   | 48 | 36 | 15         | 25  | 2   | 7 | 1     | 5   | 24 |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 6)                   |              | 0.592| 0.357| 1.0 | 0.22 | 0.004      | 0.730| 0.026| 1.0| 1.0   | 0.056| 0.007|
| dsDNA                     |              |      |     |    |    |            |     |     |   |       |     |    |
| Positive                  |              | 1    | 3    | 2  | 14 | 33          | 9   | 23  | 1 | 3     | 3   | 9  |
| (n = 80)                  |              | 0.4  | 0.0   | 0  | 36 | 7          | 5   | 7   | 1 | 4     | 0   | 1  |
| Negative                  |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 43)                  |              | 4    | 4    | 0   | 36 | 7          | 5   | 7   | 1 | 4     | 0   | 1  |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 26)                  |              | 0.05 | 0.238| 0.542| 0.156| 0.005      | 1.0  | 1.0  | 1.0| 0.238| 0.551| 0.163|
| LAC                       |              |      |     |    |    |            |     |     |   |       |     |    |
| Positive                  |              | 1    | 2    | 1  | 1   | 4          | 0   | 0   | 1 | 0     | 0   | 2  |
| (n = 7)                   |              | 0.240| 0.072| 0.197| 0.245| 0.219      | 1.0  | 1.0  | 1.0| 1.0   | 0.609| 0.550|
| Negative                  |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 126)                 |              | 4    | 7    | 3  | 50 | 40          | 13  | 31  | 2 | 7     | 3   | 10 |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 16)                  |              | 0.05 | 0.238| 0.542| 0.156| 0.005      | 1.0  | 1.0  | 1.0| 0.238| 0.551| 0.163|
| B2GP1 IgG Positive        |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 2)                   | 1            | 2    | 1    | 1  | 4   | 0          | 0   | 0   | 0 | 0     | 0   | 1  |
| Negative                  |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 106)                 | 5            | 7    | 2    | 43 | 34 | 10          | 21  | 1   | 6 | 3     | 11  | 19 |
| Missing                   |              |      |     |    |    |            |     |     |   |       |     |    |
| (n = 41)                  |              | 0.240| 0.072| 0.197| 0.245| 0.219      | 1.0  | 1.0  | 1.0| 0.367| 1.0 | 0.377|

**MC** = miscarriage; **IUFD** = intrauterine fetal death; **PTB** = preterm birth; **CS** = Caesarean section; **LN** = lupus nephritis; **APH** = antepartum haemorrhage; **PPH** = postpartum haemorrhage; **E** = eclampsia; **Pre-E** = preeclampsia; **DVT** = deep vein thrombosis; **PE** = pulmonary embolism; **HTN** = hypertension; **DM** = diabetes mellitus; **APS** = antiphospholipid syndrome; **SSA** = Sjögren syndrome-A; **SSB** = Sjögren syndrome-B; **C3** = complement 3; **dsDNA** = double stranded DNA; **LAC** = lupus anticoagulant; **B2GP1** = beta-2 glycoprotein 1 antibodies; **ACA** = anti-cardiolipin antibody; **IgG** = immunoglobulin G; **IgM** = immunoglobulin M.
Vitamin D3 level, 80 (53.69%) women were deficient (Vitamin D [25-OH] <50 nmol/L) while 52 (34.9%) were insufficient (Vitamin D [25-OH] 50–75 nmol/L). Out of 149 pregnancies, 139 (93.3%) were live births, six (4.02%) ended in a miscarriage and four (2.7%) were complicated by IUFD between 26–28 gestational weeks. Of the live births, 92 (66.1%) were vaginal deliveries and 47 (33.8%) were through CS mainly for obstetrical reasons, including previous CSs, severe preeclampsia or eclampsia. The mean gestational age at delivery was 36 ± 2 (range: 26–40) weeks. A total of 55 (39.6%) deliveries were preterm (i.e. <37 gestational weeks). Of those pregnancies, 35 (63.6%) occurred late preterm (i.e. >34 gestational weeks).

Out of the 92 vaginal deliveries, 89 (96.7%) were spontaneous while the other three (2.2%) were assisted vaginal deliveries via forceps or a vacuum device due to either non-reassuring fetal heart rate patterns on cardiotocogram or maternal exhaustion [Table 2].

The association between clinical and laboratory markers of disease in pregnant women with SLE and certain adverse pregnancy outcomes was analysed [Table 3]. Age was not a predictor for any of the adverse pregnancy outcomes. The association between preexisting HTN during the current pregnancy and several pregnancy outcomes was assessed. Significant associations were found between HTN and miscarriage ($P = 0.024$) and preterm birth ($P = 0.019$). In addition, HTN was positively associated with preeclampsia ($P = 0.004$) and LN ($P = 0.048$). DM was found to significantly affect the risk of DVT ($P = 0.013$) and increase PE risk, but this finding was not statistically significant ($P = 0.061$). Women who had three or more previous miscarriages had a higher risk of miscarriage in the current pregnancy (4/13 with recurrent miscarriage versus 2/129 without recurrent miscarriage) (OR = 19.8, 95% CI = 2.5–228.9; $P = 0.0016$).

APS impacted preterm birth ($P = 0.013$) and PPH ($P = 0.027$) and was found to be a significant predictor for developing DVT and PE ($P <0.001$ for both). All patients with APS received low dose aspirin and prophylactic doses of low molecular weight heparin (Enoxaparin).

On studying the impact of Anti Sjögren’s syndrome antibodies on adverse maternal outcomes, no clear influence was found for either anti-SSA or anti-SSB on any adverse pregnancy outcomes except

| Clinical and Lab findings | MC | Fetal Loss | IUFD | PTB | CS | LN | Joint pain | APH | PPH | E | Pre-E | DVT | PE |
|--------------------------|----|------------|------|-----|----|----|------------|-----|-----|---|-------|-----|----|
| B2GP1                    |    |            |      |     |    |    |            |     |     |   |       |     |    |
| Negative (n = 96)        | 4  | 5          | 1    | 34  | 33 | 11 | 21         | 1   | 4   | 3 | 10    | 15  | 8  |
| Missing (n = 33)         |    |            |      |     |    |    |            |     |     |   |       |     |    |
| P value                  | 0.665 | 0.283    | 0.279 | 0.03 | 0.941 | 0.690 | 0.517        | 1.0  | 0.068 | 1.0 | 1.0    | 1.0 | 0.179 | 0.367 |
| ACA                      |    |            |      |     |    |    |            |     |     |   |       |     |    |
| IgG Positive (n = 8)    | 0  | 1          | 1    | 5   | 0  | 0  | 1          | 0   | 3   | 0 | 0     | 3   | 2  |
| Negative (n = 106)      | 5  | 7          | 2    | 40  | 37 | 10 | 26         | 1   | 4   | 3 | 9     | 18  | 11 |
| Missing (n = 35)        |    |            |      |     |    |    |            |     |     |   |       |     |    |
| P value                  | 1.0 | 0.452          | 0.198 | 0.266 | 0.052 | 1.0 | 0.678 | 1.0 | 0.007 | 1.0 | 1.0    | 1.0 | 0.163 | 0.226 |
| Vitamin D3              |    |            |      |     |    |    |            |     |     |   |       |     |    |
| Deficient (n = 80)      | 3  | 4          | 1    | 33  | 22 | 5  | 22         | 1   | 5   | 2 | 8     | 15  | 7  |
| Sufficient (n = 52)     | 5  | 5          | 2    | 21  | 24 | 9  | 11         | 0   | 1   | 1 | 2     | 8   | 6  |
| Missing (n = 17)        |    |            |      |     |    |    |            |     |     |   |       |     |    |
| P value                  | 0.680 | 0.316 | 0.561 | 0.850 | 0.039 | 0.079 | 0.411 | 1.0 | 0.402 | 1.0 | 0.314 | 0.618 | 0.599 |

MC = miscarriage; IUFD = intraterine fetal death; PTB = preterm birth; CS = Caeacian section; LN = lupus nephritis; APH = antepartum haemorrhage; PPH = postpartum haemorrhage; E = eclampsia; Pre-E = preeclampsia; DVT = deep vein thrombosis; PE = pulmonary embolism; HTN = hypertension; DM = diabetes mellitus; APS = antiphospholipid syndrome; SSA = Sjögren syndrome-A; SSB = Sjögren syndrome-B; C3 = complement 3; dsDNA = double stranded DNA; LAC = lupus anticoagulant; B2GP1 = beta-2 glycoprotein 1 antibodies; ACA = anti-cardiolipin antibody; IgG = immunoglobulin G; IgM = immunoglobulin M.
for an association between anti-SSA/anti-Ro and a lower risk of CS ($P = 0.027$).

The study showed a significant association between low C3 levels and preeclampsia ($P = 0.007$) and a trend towards an increased risk of eclampsia which was just below the level of significance ($P = 0.056$). In addition, low C3 levels were associated with increased risk of CS ($P = 0.004$) and joint pain ($P = 0.026$).

While studying the impact of high anti-dsDNA level on adverse maternal outcomes, a significant association with miscarriage ($P = 0.05$) and CS ($P = 0.005$) was reported. Positive LAC anti-B2GP1-IgG was not associated with adverse outcomes. On the contrary, anti-B2GP1-IgM was significantly associated with preterm birth ($P = 0.03$) and caused a higher risk of PPH, but the association was not statistically significant ($P = 0.068$). The only significant associations between adverse outcomes and aCL antibodies were between aCL-IgM and pre-term birth ($P = 0.029$) and between aCL-IgM and preeclampsia ($P = 0.007$) and between aCL-IgG and PPH ($P = 0.022$). Vitamin D levels did not influence pregnancy outcomes except for an unexpected association of higher Vitamin D levels (>50 nmol/L) with a higher risk of CS ($P = 0.039$).

Using multivariable regression of the main adverse outcomes of pregnancy, miscarriage was found to be significantly predicted by HTN ($OR = 25.8, 95\% CI = 2.8–231.3; P = 0.004$) and dsDNA ($OR = 0.07, 95\% CI = 0.005–0.81; P = 0.034$). Prematurity was determined by HTN ($OR = 4.2, 95\% CI = 1.2–14.9; P = 0.026$), APS ($OR = 3.8, 95\% CI = 1.2–11.9; P = 0.022$) and aCL-IgM ($OR = 4.1, 95\% CI = 0.8–26.7; P = 0.091$) but not by anti-B2GP1-IgM ($OR = 0.8, 95\% CI = 0.2–3.4; P = 0.789$). Multivariable analysis showed that CS risk was only influenced by positive anti-dsDNA ($OR = 4.7$, 95\% CI = 1.4–15.4; $P = 0.048$) and higher vitamin D levels ($OR = 2.8, 95\% CI = 1.2–6.8; P = 0.02$). PPH had a significant association only with aCL-IgG ($OR = 10.7$, 95\% CI = 1.7–67.6; $P = 0.012$). Preeclampsia was almost equally determined by both HTN and low C3, with ORs of 14.4 and 15.3, respectively ($95\% CI = 2.4–86.3$ and 2.8–85.2, respectively) and $P$-values of 0.003 and 0.002, respectively. DVT was found to correlate with DM ($OR = 8.9, 95\% CI = 1.9–42.8; P = 0.006$) and APS ($OR = 87.2, 95\% CI = 17.8–427.7; P < 0.001$).

As discussed above, prematurity was seen in 50 babies, and four suffered an IUFD. Mean birth weight in the study sample was 2.72 ± 0.673 kg; range: 0.525–4.25 kg). IUGR was observed in 49 babies (35\%) mainly due to preterm birth ($n = 34$). In total, 11 newborns had an Apgar score of less than seven at one minute, and only three had a score of less than seven at five minutes. About one-third of the neonates ($n = 45; 33\%$) were admitted to the neonatal intensive care unit (NICU) due to respiratory distress, neonatal sepsis or prematurity and one neonate suffered from intraventricular haemorrhage. No neonatal lupus or congenital heart block was seen in the study sample.

APS significantly predicted prematurity ($P = 0.013$). Fetal loss was also found to be higher in patients with APS and among those who were LAC positive, but the associations did not reach statistical significance ($P = 0.064$ and 0.072, respectively).

**Discussion**

This study looked into various pregnancy outcomes and predictors that resulted in complications. In this study, most pregnancies (93.3\%) resulted in live births. The incidence of live births in pregnancies complicated by SLE was reported as ranging from 72–89\% in larger studies done in Argentina and North America. In contrast, an Egyptian study reported a much lower incidence (45–50\%). The higher live birth rate in this study could be attributed to good disease control but could also be due to the fact that the current patients were in clinical remission before conception except for one case who was in flare during pregnancy, and that case resulted in IUFD. Most pregnancies ended with a normal vaginal delivery (64\%), while 33.8\% were delivered by CS and 4\% resulted in miscarriage. Preterm delivery occurred in 39.6\% of the pregnancies and mostly in late preterm after 34 gestational weeks. In a previous prospective study in California that included 91 SLE pregnancies, a higher rate of CS deliveries (53\%) was seen, while only 32\% had a normal vaginal delivery. A similar rate of preterm birth was reported in previous studies, with the rate reaching up to 54\%. The current results showed six cases of miscarriage (4\%). A miscarriage incidence of 11–24\% was reported in SLE pregnancies in a prospective study in France. On the other hand, a range of fetal loss rates were reported in rheumatic disease clinics in North America, with cases occurring in 10\% of mild LN cases and in up to 60\% of severe cases. In contrast, this study found four (2.7\%) women with fetal loss and only one of the women had LN. In general, the fetal loss rate is comparable to healthy women (8–12\%) for women with inactive SLE at conception.

Despite improvements in pregnancy management in patients with SLE, adverse pregnancy outcomes and higher perinatal morbidity and mortality risk are still noticed in comparison with pregnant women without SLE, even among those who are in clinical remission. In this retrospective cohort study, preeclampsia was observed in 7.4\% of the patients while ranges from 3–26\% were reported in similar studies in Argentina. Nevertheless, only 2\% of the current patients progressed to eclampsia. The current...
study reported 12.08% of patients with LN during pregnancy while another similar study reported higher rates (21%). This variation might be explained by good disease and HTN control in the current patient cohort.

Autoantibodies and ANA serve as key diagnostic and classification criteria for SLE, with the latter being recently used as entry criteria for diagnosing SLE. ANA was detected in only 56% of the current cohort, which is lower than expected. This finding could be explained by low numbers in the cases studied, variability in testing protocols, type of assay used or not repeating the testing. A recent study concluded that ANA is not always found in SLE patients. The researchers reported negative and fluctuating ANA results in 36.9% and 33.3% of patients, respectively. Another study found ANA positivity in only 23.7% of patients.

This study examined various predictors that resulted in adverse pregnancy outcomes. A significant association was found between HTN and miscarriage, preterm birth, pre-eclampsia and LN. Similarly, a study done at the University of California Davis School of Medicine reported a significant association between HTN and miscarriage as well as preterm birth (P = 0.001 and 0.017, respectively). An increased risk of developing preeclampsia and LN was also found in previous studies.

APS is frequently seen in patients with SLE and may result in various pregnancy-related complications. APS was found in 16.78% of the pregnancies in the current cohort. Similarly, a meta-analysis reported its presence in approximately one-quarter of the pregnancies in which the mother had been diagnosed with lupus. The presence of APS is strongly associated with the development of DVT, PE and fetal loss but, in the current study, the latter did not reach statistical significance. Previous studies have reported similar outcomes.

A study conducted in Mexico of 1,334 pregnant women with SLE reported low C3 levels in almost 50% of the patients. This finding is considered a very high incidence in comparison with the current finding as only 14.09% of the current cohort had low C3 levels. Patients with low C3 levels were more likely to deliver via CS, but this observation could be related to obstetrical indications. More research is needed in order to establish the possibility of a causal relationship.

Preeclampsia in the current study was exacerbated by low C3 level. Patients with low C3 level were 15 times more likely to develop preeclampsia than those with normal C3 levels (OR = 15.3). In contrast, other studies have shown positive associations between preexisting renal disease and HTN. This finding was not present in the current study probably because of a limited sample size. In comparison, eclampsia was only present with a decreased level of C3 (P = 0.035).

The presence of anti Ro/SSA and anti La/SSB antibodies has been associated with neonatal lupus and congenital heart block (CHB) in previous studies. None of the current neonates, however, had neonatal lupus or CHB, perhaps due to the finding that maternal antibodies were low in this cohort. In addition, the current patients were on hydroxychloroquine, which is usually associated with a lower risk of CHB.

This study successfully detected factors that can be used as indicators to determine women with SLE who might be at risk of adverse pregnancy outcomes. A significant relationship was found between HTN and preterm birth, preeclampsia, LN and miscarriage. These findings along with those of other practitioners can be used to establish guidelines to help doctors treat and manage pregnant women with SLE, thus resulting in successful outcomes.

This study has multiple limitations including a small sample size which is due to the small population in Oman compared to other countries and the fact that it was conducted in a single tertiary centre. However, the study was sufficiently powered (85%) to detect a rate of preeclampsia of up to 22.5% and predict the effect of HTN on preeclampsia. In total, 45% of hypertensive women in the current study developed preeclampsia. A significant drawback was that this study did not look at SLE pharmacological management and its relation to various pregnancy outcomes. Finally, a comparative study with healthy pregnant women is recommended to solidify knowledge and guideline development.

Conclusion

Although most pregnancies complicated by SLE have good outcomes, adverse outcomes may still occur in women with SLE. Planning pregnancies and careful pregnancy monitoring coupled with efficient treatment need to be enhanced for successful outcomes. Further studies which include larger sample sizes and multiple centres caring for women with SLE are recommended.

ACKNOWLEDGEMENT

The abstract was submitted and presented at the 22nd FIGO conference, Rio de Janeiro, Brazil, 14–19 October 2018.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.
FUNDING
No funding was received for this study.

References

1. Andreoli T, Fredi, M, Nalli C, Reggia R, Lojacono A, Motta M et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun. 2012; 38:1197–1208. https://doi.org/10.1016/j.jaut.2011.11.010.

2. Mecacci F, Pieralli A, Bianchi B, Paidas M. The impact of autoimmune disorders and adverse pregnancy outcome. Semin Perinatol.2007;31:223–6.https://doi.org/10.1053/j.semper.2007.05.005.

3. Rees E, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 2016; 75:135–41. doi.org/10.1136/annrheumdis-2014-206334.

4. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199:1271–e6. https://doi.org/10.1016/j.ajog.2008.03.012.

5. Porth, C, Gaspard K. Essentials of Pathophysiology, 1st ed. Philadelphia: Wolters Kluwer, 2015.

6. Gómez-Puerta J, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2007; 27:1679–86. https://doi.org/10.1177/0961203318787032.

7. Nihal Al Riyami, Bustria Salmon, Aamer Ali Rashdi, Tamima Al Dughnaishi, Rahma Al Haddabi and Batool Hassan

8. Borchers A, Naguwa S, Keen C, Gershwin M. The implications of systemic lupus erythematosus (SLE). Clinical Rheumatol 2007; 26:330–7. https://doi.org/10.1007/s10067-006-0649-3.

9. Aly EAH, Riyad MR, Mobkel AN. Pregnancy outcome in patients with systemic lupus erythematosus: A single center study in the High Risk Pregnancy Unit. Middle East Fertil Soc J 2016; 21:168–74. https://doi.org/10.1016/j.mefsk.2015.12.003.

10. Smyth A, Oliveira G, Lahr B, Bailey K, Norby S, Garovic V. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5:2060–8. https://doi.org/10.2215/CJN.00240110.

11. Hoehberg M.C. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum 1997; 40:1725. https://doi.org/10.1002/art.1790400928.

12. NHS UK. Pre-eclampsia—NHS choices. From: www.nhs.uk/Conditions/Pre-eclampsia/Pages/Introduction.aspx Accessed: Jul 2020.

13. Healthline. Eclampsia. From: www.healthline.com/health/eclampsia. Accessed: Mar 2017.

14. Rosalba Giordano M. Antepartum haemorrhage. From: www.ncbi.nlm.nih.gov/pmc/articles/PMC3263934/ Accessed: Jul 2020.

15. Emedicine Medscape. Postpartum hemorrhage: Background, problem, epidemiology. From: emedicine.medscape.com/article/275038-overview Accessed: Jul 2020.

16. Lefete A, Petri M. Systemic lupus erythematosus and pregnancy. Rheumatic Dis Clin North Amer 2017; 43: 215–26.

17. Cavallasca J, Laborde H, Ruda Vega H, Nasswetter G. Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE). Clinical Rheumatology 2007; 27:41–6. https://doi.org/10.1007/s10067-007-0649-3.

18. Pastore DEA, Costa ML, Surita FG. Systemic lupus erythematosus and pregnancy: The challenge of improving antenatal care and outcomes. Lupus 2019; 28:1417–26. https://doi.org/10.1177/0961233319877247.

19. Hsueng D, Wechsler R, Vauthier-Brouzes D, Beaufils H, Lefebvre G, Piette J. Pregnancy in past or present lupus nephritis: A study of 32 pregnancies from a single centre. Ann Rheum Dis 2001; 60:599–604. https://doi.org/10.1136/ard.60.6.599.

20. Dhar J, Essennacher L, Ager J, Sokol R. Pregnancy outcomes before and after a diagnosis of systemic lupus erythematosus. Am J Obstet Gynecol 2005; 193:1444–55.

21. Yan Yuen S, Krizova A, Ouimet M, Pope J. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review. Open Rheumatol J 2008; 2:89–98. https://doi.org/10.2174/18743129080802010089.

22. Phanseene S, Sekararishi R, Jatavan P, Tongsong T. Pregnancy outcomes among women with systemic lupus erythematosus: A retrospective cohort study from Thailand. Lupus 2018; 27:158–64. https://doi.org/10.1177/0961233317721353.

23. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/AMERICAN College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71:1400–12. https://doi.org/10.1002/art.40930.

24. Fritzl MF, Choi MY. Autoantibodies in SLE: Prediction and the p value matrix. Lupus 2019; 28:1285–93. https://doi.org/10.1177/0961233319868531.

25. Tarazi M, Gaffney RG, Kusner CJ, Chakka S, Werth VP. Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2019; 71:1404–9. https://doi.org/10.1002/acr.23916.

26. Yavuz GO, Yavuz IH, Bayram I, Aktar R, Bilgili SG. Clinic experience in discoid lupus erythematosus: A retrospective study of 132 cases. Adv Dermatol Allergol 2019; XXXVI:17–39. https://doi.org/10.11141/ad.2018.77726.

27. Maynard S, Guerrier G, Duffy M. Pregnancy in women with systemic lupus and lupus nephritis. Adv Chronic Kidney Dis 2019; 26:330–7. https://doi.org/10.1016/j.ackd.2019.08.013.

28. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: A systematic review and meta-analysis. Obstet Gynecol 2010; 116:1433–43. https://doi.org/10.1097/OGO.0b013e3181fe02ec.

29. Yelnik CM, Lambert M, Drumez E, Le Guern V, Bacri J-L, Laskin CA, et al. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus 2018; 27:1679–86. https://doi.org/10.1177/0961233318787032.

30. Rezk M, Dawood R, Badr H. Maternal and fetal outcome in women with antiphospholipid syndrome: A three-year observational study. J Matern Fetal Neonatal Med 2016; 29:4015–9. https://doi.org/10.1177/14767058.2016.1152254.

31. de Jesus GR, Mendoza-Pinto C, de Jesus NR, Dos Santos FC, Klumb EM, Carrasco MG, et al. Understanding and managing pregnancy in patients with lupus. Autoimmune Dis 2015; 2015:943490.1–18. https://doi.org/10.1155/2015/943490.

32. Jæger E, Laskin C, Hamilton R, Kingdon J, Silverman E. The importance of the level of maternal anti-RO/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: A prospective study of 186 antibody-exposed fetuses and infants. J Amer Coll Cardiol 2010; 55:2778–84. https://doi.org/10.1016/j.jacc.2010.02.042.
33. Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda A, Arnálich-Fernández F, Martín Cameán M, Hueso Zalvide E, et al. Obstetric and perinatal outcome in anti-RO/SSA-positive pregnant women: A prospective cohort study. Immunol Res 2017; 65:487–94. https://doi.org/10.1007/s12026-016-8888-5.

34. Barsalou J, Costedoat-Chalumeau N, Berhanu A, Fors-Nieves C, Shah U, Brown P, et al. Effect of in utero hydroxychloroquine exposure on the development of neonatal lupus erythematosus. Ann Rheum Dis 2018; 77:1742–9. https://doi.org/10.1136/annrheumdis-2018-213718.

35. Do SC, Druzin ML. Systemic lupus erythematosus in pregnancy: High risk, high reward. Curr Opin Obstet Gynecol 2019; 31:120–6. https://doi.org/10.1097/GCO.0000000000000528.